Trial Profile

A proof-of-concept Phase I study of BT-409 in Parkinson's disease

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BT 409 (Primary)
Indications Parkinson's disease
Focus Adverse reactions; Proof of concept
Sponsors Brenig Therapeutics

Most Recent Events

03 Feb 2026 New trial record
02 Feb 2026 According to Mwyngil Therapeutics media release, company announced the initiation of a Phase 1 clinical study of BT-409, a potentially best-in-class, brain-permeable NLRP3 inhibitor being developed for multiple sclerosis (MS), Parkinson's disease (PD), and other neuroinflammatory indications.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com